Moreover, this compound induced PARP cleavage and increased BAX expression, whereas BCL2 expression was downregulated after lj-1-59 treatment in different melanoma cell lines (Fig. 3c and Additional file 1: Fig. S2e). The gene discussed is BCL2; the disease is melanoma.